Newsletter · · Ashutosh Agarwal

The Biotech Patent Cliff & M&A - Week of June 12, 2026: Biopharma Deals Tripled, and Washington Takes Aim

Biotech M&A and patent-cliff newsletter for the week of June 12, 2026. RBC's bankers quantified the supercycle with billion-dollar life-sciences deals tripling year over year, a new bipartisan bill put US-China pharma deals under Treasury review and named Pfizer and Bristol-Myers, and Merck restated its post-Keytruda diversification plan.

The Biotech Patent Cliff & M&A

Week of June 12, 2026: Biopharma Deals Tripled, and Washington Takes Aim

After last Friday's silence, the tape woke up. This week we got two things that matter: hard numbers on just how hot the life-sciences M&A market has become, straight from the bankers cutting the deals, and a fresh legislative threat to the China pipeline that big pharma has been quietly relying on to backfill its patent cliffs. The cliff-defense playbook also got a clean restatement from Merck's head of R&D. Here's what a PM needs.

TL;DR

  • Billion-dollar life-sciences deals tripled over the last four quarters (33+ vs. 11 in the prior four), per RBC's M&A co-head, with patent cliffs named explicitly as a driver. Premiums are compressing toward low-double-digits and CVRs are everywhere.
  • A new bipartisan bill (June 2) would drag US-China pharma and biologics deals under Treasury review and named Pfizer and Bristol-Myers by name, a direct shot at the China-licensing route pharma is using to refill pipelines ahead of the 2028 wall.
  • Merck reframed its Keytruda 2028 cliff defense: 44 indications, subcutaneous Qulex launched in 2025, a $6.7B Terns deal into heme-malignancies, and a claimed >$25B late-stage commercial opportunity by 2030.

What's New

The deal count tripled, and the bankers are saying it out loud. This is the number of the week. On Pathfinders in Biopharma, "Big-value deals set the pace in healthcare M&A" (June 9), David Levin, Co-Head of US M&A at RBC Capital Markets, put hard figures on the supercycle: "if you look over the last four quarters... $33 billion-plus deals in life sciences. If you look at the four quarters prior to that, there were 11. So triple the number of billion-dollar deals." He named patent cliffs directly as a driver, "They've got cliffs that they're facing in some cases," alongside proactive pipeline-building, and flagged Lilly, Novartis, Merck, Gilead and Biogen as active acquirers. This is operator color, not a pundit's guess: it's the banker on the deals.

Premiums are compressing and CVRs are the norm. Same episode, same source. Levin: biotech premiums that were "historically triple digits or high double digits" have shifted over the last 18 months to "a lot more low double-digit premiums," and counterintuitively, he thinks that helps fuel volume. On structure: "CVR is also a feature and... over the last 18 months, perhaps a little bit more heavy as a way to bridge gaps." Translation for the book: sellers are accepting smaller upfronts with contingent value to close the bid-ask, and competitive auctions are bidding "up to the finish line." Cheaper control premiums plus risk-shifting CVRs are exactly the conditions that keep a deal machine running.

Washington just put the China pipeline route on notice. On Citeline Podcasts, "Scrip's Five Must-Know Things - June 8, 2026" (June 8), reporter Jessica Merrill flagged the Biotech Investment National Security Act, introduced June 2, which would "increase scrutiny of pharmaceutical development, biologics manufacturing, and clinical research and development deals between US and Chinese manufacturers." Rep. Moolenaar "named Pfizer and Bristol-Myers as American companies making dangerous deals with Chinese biotech," citing Bristol's "sweeping R&D alliance with Jiangsu Hengrui Pharmaceuticals spanning 13 preclinical programs." Why it matters: as Citeline put it, pharma is "increasingly turning to China to mine R&D laboratories for new assets to refill their pipelines amid looming major losses of exclusivity." This is regulatory context, not market opinion, but it puts sand in the gears of one of the cheaper pipeline-backfill strategies of the cycle.

Merck restated the Keytruda 2028 defense, and it's about diversification, not heroics. On the same Citeline episode, Dean Li, President of Merck Research Labs (operator), laid out the franchise plan from ASCO: two 2021 objectives, "to maximize the positive impact of Keytruda, especially in earlier stages of disease, and to diversify our pipeline with novel mechanisms." The scorecard: 44 Keytruda indications (11 in earlier-stage settings), the subcutaneous Keytruda Qulex launched in 2025 as the core formulation-defense move, 14 new oncology drugs and 80+ indications targeted by 2030, 60 Phase 3 trials running, and a claimed >$25B commercial opportunity from the late-stage pipeline. The $6.7B Terns acquisition gets folded in here too: Li framed it as Merck's entry into hematologic malignancies, "3 hematologic assets with Phase 3 data expected in 2027," adding "multibillions additionally" on top of the $25B.

The LOE cliff is now showing up in the proxy statements. Citeline's Edwin Elmhurst (reporter, citing disclosure) noted J&J's board awarded CEO Joaquin Duato a 145% long-term incentive payout "in recognition of what it described as the company having overcome its most significant loss of exclusivity event in more than a decade, with the Stelara biosimilar entry." AbbVie's Robert Michael booked $32.5M, up sharply from Gonzalez's $24.3M, a confidence signal on the post-Humira Skyrizi/Rinvoq rebuild. Tellingly, Merck and Novo were the only two large-cap pharma CEOs whose pay fell year-over-year, which Elmhurst read as a capital-conservation posture into the cliff.

The Debate

This week the tape was lopsided toward the bull case, and that's worth saying plainly rather than manufacturing a bear to balance it. The supercycle thesis got the strongest, most specific support: a banker quantifying a 3x jump in billion-dollar deals, premium compression that expands the buyable universe, CVRs to bridge valuation gaps, and named cliff-driven acquirers. The bear case wasn't argued by anyone directly this week. The closest thing to a counterweight came from the regulatory side, the China-deal bill and a general "reimbursement policy overhang" that RBC's Ahmed Atiyah said "has definitely had an impact" on policy-exposed assets. Notably absent from the seven-day tape: any FTC domestic-deal-review commentary, IRA pill-vs-biologic selection dynamics, or a valuation-discipline skeptic warning that pharma is overpaying. The integration-risk and antitrust bears simply weren't voiced, file the one-sidedness itself as a data point.

The Names In Play

This was more of a thematic week than a single-name week, but a few names genuinely moved:

  • MRK: most concrete operator narrative, the Qulex subcu defense, 80+ indications by 2030, $6.7B Terns into heme, and the >$25B pipeline claim. Also flagged among CEOs cutting pay (a conservation posture).
  • PFE / BMY: both named in the China-deal bill; BMY's 13-program Hengrui alliance is the explicit target. A real, if early, friction point for their pipeline-backfill math.
  • JNJ / ABBV: proxy data as a cliff-management read, J&J's Stelara transition declared "overcome," AbbVie's comp jump signaling confidence in the Skyrizi/Rinvoq recovery.

Read-Throughs

  • SMID-cap and financing: RBC's Jason Levitz (ECM head) said there have been "more $500 million-plus transactions in equity capital raises by public biotech companies this year than in the prior three years combined and we're only in May," much of it going to still-clinical-stage "winners." Capital is concentrating in de-risked oncology, immunology/inflammation and CNS names, exactly the validated platforms strategics shop for. IPO appetite favors lower-clinical-risk assets.
  • Rare disease is the mid-cap hunting ground, per Levin, "specialized sales forces and products that are more insulated from competition," an indirect LOE hedge.
  • Bankers and structuring: equity rollover (5–20% seller retention) is creeping into sponsor deals on asset scarcity, and foreign buyers are chasing US manufacturing capabilities on onshoring policy, a net positive for inbound deal flow. No biosimilar-maker or CRO-specific commentary surfaced this week.

What Changed

Last week I told you straight that the tape was quiet, no citable podcast commentary on cliffs or M&A at all. This week it flipped hard: actual deal-volume data from the bankers running the book, a fresh legislative catalyst with two large-caps named, and a clean operator restatement of the Keytruda defense. The signal moved from "nothing to report" to "supercycle confirmed, with a new policy risk to watch."